Clinical Trial Update: Registry Study of Revcovi Treatment in Patients With ADA-SCID

View source ↗

Summary

Registry study evaluating Revcovi for ADA-SCID has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenosine Deaminase Severe Combined Immunodeficiency

Drugs mentioned

• Revcovi (elapegadamase-lvlr)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Adenosine Deaminase Severe Combined Immunodeficiency | Status: COMPLETED | Results posted: 2024-11-15